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The Predictive Value of Platelet Function point-of-care Tests for Postoperative Blood 
Loss and Transfusion in Routine Cardiac Surgery: a systematic review 
 
ABSTRACT 
Excessive bleeding after cardiopulmonary bypass (CPB) operations remains to be a persistent 
problem and weak platelet function certainly contributes to bleeding diathesis. Antiplatelet 
therapy (APT) is an integral component of perioperative management in patients undergoing 
cardiac surgery procedures, both with and without use of CPB. In addition to individual 
variability in platelet function, different preoperative APT administration/discontinuation 
management further affects platelet function which in turn may reflect bleeding tendency. 
However, the impact of drug induced platelet inhibition on early postoperative bleeding 
extent, however, remains difficult to predict. Herein, we reviewed the available evidence on 
the association between platelet function testing values and the extent of bleeding and 
transfusion requirements in early perioperative period. Currently, the association between 
platelet function measured by ex vivo assay and the occurrence of bleeding events remains 
uncertain. The intent of this review is to provide comprehensive literature insight into 
published evidence investigating the possibility of platelet function tests to predict bleeding 
extent as well as transfusion requirements in cardiac surgery patients. 
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INTRODUCTION 
Bleeding extent as well as transfusion of allogeneic blood products certainly affect 
outcome following cardiac surgery procedures. Up to 10% of patients undergoing cardiac 
surgery experience excessive postoperative hemorrhage[1]. Christensen et al investigated the 
relationship between postoperative hemorrhage and clinical outcome following cardiac 
surgical procedures [2]. Patients that experienced excessive postoperative bleeding had higher 
30-day mortality and other adverse outcomes such as stroke, reexploration, intensive care unit 
stay and mechanical ventilation[2]. Those findings are in line with results reported by Dixon 
et al [3]. Authors undertook a multivariate logistic regression analysis of the risk factors 
associated with mortality in 2599 consecutive patients undergoing cardiac surgery [3]. With 
aim to consider the possibility that chest tube drainage (CTD) may in itself be harmful, the 
risk factors examined included the volume of CTD at 24 hours[3]. CTD was the strongest 
independent predictor of mortality (p<0.001) [3]. Although results reported by Dixon et al [3] 
have numerous implications for surgical practice, the question how to predict and prevent 
excessive CTD, remains challenging. The meticulous hemostatic surgical technique is 
mandatory [4], however sometimes is insufficient to achieve adequate hemostasis, probably 
due to coagulopathic component of bleeding.  
Platelet function plays important role in pathogenesis of hemostatic disorder and 
consequent bleeding diathesis in cardiac surgery patients. Platelet function may be considered 
as a continuous variable that expresses widespread range among individuals. Widespread 
range of platelet activity among individuals arises from different factors such as: 1)  
widespread interindividual variability in inherent platelet activity , 2)  widespread variability 
in platelet inhibitory response to antiplatelet therapy (APT) and 3) individual ability to 
recover platelet function after APT cessation, which is also influenced by timing of 
discontinuation and type of drug used. There is evidence that heritable factors play a major 
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role in determining platelet aggregation[5] and such a variability in platelet aggregation may 
in some degree explain proclivity towards bleeding as well as ischemic events. In addition to 
heritable factors, platelet function is dominantly influenced by APT. Patients experiencing the 
therapeutic effects of APT and requiring cardiac surgery are at risk for adverse bleeding 
events and transfusion requirements. Patients receiving APT have different degrees of platelet 
inhibition. Widespread variability in platelet responses to the most commonly prescribed 
antiplatelet drugs such as acetylsalicylic acid (ASA) and clopidogrel (CLO) have been 
established by various platelet function assays [6]. The bleeding risk has recently become 
accentuated by the widely prevalent dual antiplatelet therapy with ASA and CLO. Despite the 
current guidelines, many centers continue with APT up to day of surgery, disregarding the 
recommendations for a drug free interval before surgery. For example, data from 2858 acute 
coronary syndrome patients in the CRUSADE (Can Rapid risk stratification of Unstable 
angina patients Suppress ADverse Outcomes with Early implementation of the ACC/AHA 
Guidelines) Initiative demonstrated that 87% of CLO treated patients underwent CABG ≤ 5 
days after treatment with a consequently increased blood transfusion requirement [7]. 
Notably, 5-15% of patients with an acute coronary syndrome require an urgent cardiac 
operation with recently administered antiplatelet drugs [7].  
The considerable heterogeneity in platelet inhibitory response to APT makes it 
difficult to safely use arbitrary interval for drug discontinuation prior to surgery without 
incurring excessive thrombotic or bleeding risks with premature versus too late 
discontinuation. Therefore, an individual approach in preoperative assessment of the bleeding 
risks is warranted. Bedside suitable platelet function testing could play an important role in 
the prediction and prevention of excessive bleeding after CPB. Notably, conventional 
coagulation tests have been shown to be unreliable in predicting postoperative bleeding [8,9]. 
Platelet function testing presents a kind of phenotyping approach that provides quantification 
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of platelet function by summarizing the effects of all previously mentioned covariates that 
influence platelet activity.  Theoretically, platelet function tests could guide clinical decision 
making in patients on APT. Evaluating the efficiency of platelet inhibition in the preoperative 
settings offers to identify patients in whom excessive bleeding is likely and often preventable 
[10]. Velik-Salchner et al[10] showed that bedside suitable platelet function test was capable 
to discriminate patients according to preoperative APT exposure [10] as well as to detect CPB 
induced changes in platelet aggregation[10,11]. 
Hemostatic disorders became more apparent with perioperative use of novel 
antithrombotic drugs such as prasugrel and ticagrelor. Prasugrel, third generation 
thienopyridine achieves more rapid and greater platelet inhibition than clopidogrel and is 
substantially associated with higher rates of major and minor bleeding in cardiac surgery 
patients[12,13]. Ticagrelor, novel, nonthienopyridine antiplatelet drug achieves more 
pronounced inhibition of platelet function than clopidogrel [12]. More potent antiplatelets to 
which patients are more often exposed in close proximity to surgery require prudent 
hemostatic management. Despite the fact that novel antithrombotic drugs achieve greater 
inhibition of platelet aggregation with a lower rate of non-responders [14], it is obvious that 
antiplatelet drugs act in a wide range of inhibition. Such variability may occur during the 
initiation of therapy, steady-state administration as well as after discontinuation of treatment 
with variable interval needed to achieve recovery after drug discontinuation. Consequently, 
platelet function testing seems reasonable. Use of platelet function testing may help improve 
hemostatic management by stratification of patients according to different levels of platelet 
inhibition, thus different risks of excessive bleeding due to platelet dysfunction. In this way it 
would be possible to determine “safe window” of platelet inhibition that would permit safe 
surgery in regard to bleeding risk. In certain proportion of patients APT could be discontinued 
even before the recommended waiting period and in this way it could be possible to minimize 
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both bleeding and ischemic events occurrence. Cangrelor, a reversible intravenous P2Y12 
inhibitor has a fast onset of action and very short half-life [15] which allows for precise 
temporal programming of platelet inhibition and has recently been used for bridging APT in 
patients scheduled for cardiac surgery[16]. Short-acting (eptifibatide and tirofiban) and long-
acting (abciximab) GPIIB/IIIA inhibitors cause profound platelet inhibition. Since some 
patients on GPIIB/IIIA inhibitors require emergent surgery, particular attention should be paid 
to patients on long acting agents such as abciximab. New anticoagulation agents such as 
factor Xa inhibitor rivaroxaban and apixaban and direct thrombin inhibitor such as dabigatran 
may further amplify hemostatic disorder in cardiac surgery patients. There is some evidence 
that point-of-care devices are not suitable for assessment of hemostatic disturbances caused 
with factor Xa inhibitor administration[17]. However, further elaboration on this issue goes 
far beyond the scope of this review article.  
In this article, we reviewed available evidence on the utility of platelet function testing 
in assessment of excessive bleeding as well as transfusion requirements in patients 
undergoing cardiac surgery. The intent of this review is to provide comprehensive insight into 
published evidence investigating whether platelet function tests are capable to predict 
excessive bleeding and transfusion requirements in cardiac surgery patients by matching 
quantified platelet function with evaluated endpoints such as bleeding extent and transfusion 
requirements.
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METHODS 
PUBMED and MEDLINE were searched using predefined search terms such as “platelet 
function testing” , “bleeding cardiac surgery” and “transfusion cardiac surgery” using 
Boolean logic operators [AND] and [OR]. Abstracts were evaluated, and relevant full-text 
articles were obtained. In addition to, reference lists of selected publications were analyzed 
for additional linking studies. Articles that addressed the relation between platelet function 
testing and bleeding outcomes as well as transfusion requirements in cardiac surgery patients 
were included in review. During literature review we aimed to plot platelet function testing 
against different endpoints. Excessive bleeding was defined as proposed by authors in 
respective manuscripts. Different authors proposed different ways to define excessive 
bleeding. Excessive bleeding as an endpoint was mainly defined in respect to extent of CTD 
in certain amount of time. Different amounts of CTD revealed in different timeframes were 
used and patients were defined as excessive bleeders if their CTD exceeded predefined cutoff 
value for excessive bleeding. The other important endpoint was “transfusion requirements”. 
Through searched literature we observed transfusion requirements for different procoagulant 
blood components transfusion. Although transfusion requirements for platelet concentrate 
would have clear rationale, we decided to assess for all procoagulant blood components 
transfusion requirements. In non-interventional studies where attending anesthesiologists and 
surgeons are unaware of platelet function testing results and where decision to transfuse 
procoagulant blood components relies either on institutional algorithm or solely on the 
clinical judgment, weak platelet function may cause wet field which in turn may be treated 
with different types of procoagulant blood components , depending on the institutional 
algorithm or preference of clinicians blinded to platelet function results.  
 
 
7 
 
MONITORING OF PLATELET FUNCTION IN CARDIAC SURGERY PATIENTS 
Therapeutic approach to surgically or coagulopathically-induced bleeding is quite 
different. Bedside assessment of blood hemostatic properties has several advantages over 
conventional coagulation testing.  First of all, turnaround time from sampling blood to 
obtaining results is often crucial. Although point-of-care tests show more variation and lower 
precision, the focus should be on the accuracy sufficient to make appropriate clinical 
decisions timely. Despite the fact that standard coagulation testing is focused more on 
accuracy than on turnaround time [18] conventional coagulation testing failed to predict 
postoperative bleeding in cardiac surgery patients [8,9]. In addition to, conventional 
laboratory tests are unable to decompose multifactorial pathogenesis of hemostatic disorder as 
described by Paparella et al [19]. 
Thromboelastograph (TEG) has been used in hospital laboratories since its 
development by Hartert in 1944 at Heidelberg University. Spiess et al published the first 
study evaluating the relationship between TEG and bleeding extent after cardiac surgery [8]. 
In small study cohort (38 patients) TEG was predictor of postoperative hemorrhage[8]. 
However, platelet function was only indirectly assessed since modified TEG with platelet 
function mapping was not available. Nowadays, two most commonly employed point-of-care 
devices for assessment of viscoelastic blood properties are thromboelastograph (TEG, 
Haemoscope Corporation, Niles, IL, USA) and the ROTEM thromboelastometer (TEM 
International GmbH, Munich, Germany). Differences as well as similarities between 
thromboelastography and thromboelastometry systems should be briefly elaborated. Both 
systems measure viscoelastic properties of  blood clot by employing a vertical pin held in the 
blood sample, contained within a cup[20]. Technical aspects of differences between two 
systems as well as advantages and disadvantages of one system over the other are published 
by Jackson et al in “head to head” comparison[20]. Although these two devices share the very 
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similar concept, divergent results on similar samples were reported by Nielsen et al[21]. Of 
more importance, in particular in this review article, should be noted that only TEG provides 
platelet function mapping by adding specific platelet function agonists that allow for 
quantification of platelet function through different pathways.  In addition to TEG Platelet 
Mapping, various bedside suitable , point-of-care platelet function tests have been 
increasingly used. Nowadays, several devices are available. Detailed description of mostly 
used current platelet function testing devices has been already published[22]. 
 
ASSOCIATION BETWEEN PLATELET FUNCTION TESTS FINDINGS AND 
BLEEDING OUTCOMES AND TRANSFUSION REQUIREMENTS 
Conflicting data have been published regarding ability of point-of-care platelet function 
assays to predict bleeding extent as well as transfusion requirement after cardiac surgery.  
Poston et al investigated the predictive value of platelet function testing in assessment 
of bleeding and thrombotic events after off-pump coronary artery surgery (CABG) [23]. Two 
point-of-care platelet function devices were used: (1) TEG assay using arachidonic acid 
agonist (Thrombelastograph Platelet Mapping (Haemoscope Corporation, Niles, Ill), and (2) 
Whole blood aggregometry (WBA) (model592A, Chronolog, Havertown, Pennsylvania). 
Intraoperative amount of bleeding significantly correlated with the decrease in platelet 
function as assessed by WBA (r=0.42, p<0.05), but not TEG (p=ns). The same TEG device 
failed to significantly correlate with 24 hour CTD in study by Carrol et al [24]. It should be 
noted that patients on APT were excluded from the study a priorily[24] thus making the 
cohort to be of low bleeding risk in terms of platelet dyfunction. The role of platelet function 
testing in group of patients not exposed to APT seems to be questionable. The fact is that 
platelet function testing may be of the greatest benefits in patients who are exposed to APT. 
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Contrary to, Preisman et al reported TEG parameter using adenosine diphosphate (ADP) 
agonist to significantly predict bleeding extent [25] with a sensitivity of 78% and specificity 
of 84%. Comparison between patients with normal and abnormal TEG ADP test revealed 
larger amount of 24-h CTD in group of patients with abnormal TEG ADP test[25]. In addition 
to, the same TEG parameter significantly correlated with transfusion of platelet concentrate 
(Spearman’s rho= -0.75, p=0.02). Kwak et al introduced an idea about timing of surgery 
according to TEG platelet mapping results for patients with CLO administered in proximity to 
surgery[26]. Patients were divided into three groups according to tertiles of distribution of the 
percentage of platelet inhibitory response to CLO therapy [26]. Patients in the third tertile (the 
most pronounced platelet inhibition) had a significantly greater amount of postoperative CTD 
[26]. Significantly more patients in the third tertile required packed red blood cells and fresh 
frozen plasma transfusion with higher number of units transfused than those patients with 
higher residual platelet reactivity following APT administration[26]. ROC analysis revealed 
optimal cutoff value for postoperative transfusion requirement as 70% platelet inhibitory 
response to CLO [26]. Accentuated platelet inhibitory response to CLO , but not 
discontinuation date and preoperative drug free interval, remained independent risk factor for 
transfusion requirements[26]. Weitzel et al conducted prospective observational study using 
TEG platelet mapping with adenosine-diphosphate (ADP) , arachidonic acid (AA) and 
collagen (COL) as agonists [27]. TEG platelet mapping assay with collagen as activator 
(MAcollagen) was found to be the only parameter significantly lower in high bleeding groups 
in both pre- and post-CPB setting. Furthermore, pre- and post-CPB MAcollagen significantly 
correlated with 24 hour CTD extent while only pre-CPB MAaa (Pearson correlation 
coefficient (r) -0.324, p=0.041) correlated with 24 hour CTD [27]. Although MAadp did not 
correlate significantly, it is worthwhile to mention that recent preoperative CLO exposure was 
exclusion criterion which in turn may raise the question whether the obtained results would be 
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different in lower range of MAadp values expected in patients exposed to CLO 
preoperatively. Mahla et al conducted the first prospective interventional study of a platelet 
function measurement based strategy to reduce bleeding and waiting time in CLO treated 
patients undergoing CABG (TARGET-CABG study)[28]. Platelet function testing was 
performed using TEG with ADP agonist [28]. Patients receiving CLO were divided into three 
groups according to platelet function test results and the surgery timing was adjusted for each 
group according to platelet reactivity as follows : MA-ADP >50 mm – surgery within 1 day , 
MA-ADP 35-50 mm – surgery within 3-5 days  and surgery after 5 days following CLO 
discontinuation if MA-ADP was below 35 mm. All three subgroups along with CLO naive 
patients were comparable for the primary (CTD at 24 hours) and secondary endpoints (total 
number of transfused red blood cells) [28]. Such a strategy allowed for approximately 50% 
reduction in waiting time than recommended in the current guidelines [29,30] suggesting the 
fact that uniform waiting period for discontinuation of antiplatelet drugs[29,30] as suggested 
in guidelines may be actually obsolete. 
With specific aim to evaluate whether Hemostatus – platelet activating factor clotting 
time (PACT, Hemostatus, Medtronic, Inc, Parker, CO) device findings correlate with 
postoperative blood loss, Despotis et al[31] conducted prospective observational study[31]. In 
cohort group of 150 patients undergoing cardiac surgery requiring CPB, PACT significantly 
(r=-0.85) correlated with 4 hours CTD [31]. Authors concluded that PACT may be useful tool 
for prediction of excessive bleeding [31]. Although using the same device in similar research 
and clinical setting, the study of Ereth et al [32] showed substantially opposite results to those 
published by Despotis et al[31]. PACT values obtained after protamine administration 
correlated weakly with 4 hours CTD (r=-0.30, p=0.014). However, the correlations between 
postprotamine PACT values and 24 hour CTD as well as with transfusion requirements were 
not significant [32]. PACT had comparable results to routine laboratory coagulation tests in 
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prediction of excessive hemorrhage and authors didn’t support its use in regular clinical 
practice. Furthermore, Ereth et al[33] conducted another prospective study that duplicated 
study settings of Despotis et al[31] with aim to determine the relation between PACT 
performed within one hour following intensive care unit arrival and blood loss[33]. Again, 
PACT values didn’t correlate with blood loss [33] whilst prothrombin time (PT) strongly 
correlated with CTD (p<0.0001) [33]. Notably, only PT correlated with transfusion of 
platelets and fresh frozen plasma [33]. However, this particular correlation should be 
interpreted with caution since attending physicians were unaware of only PACT results, but 
authors did not describe specific hemostatic protocol. Thus, those correlations are expected if 
procoagulant blood products administration was targeted after PT values.  
Dietrich et al conducted prospective study with aim to investigate the relationship 
between platelet function tests (four different methods: TEG, modification of impedance 
aggregometry, PFA-100 ® and platelet function PAF test) and postoperative bleeding extent 
in cardiac surgery patients[34]. Postoperative CTD could not be predicted by platelet function 
tests performed preoperatively[34]. However, this findings should be interpreted cautiously 
since the study enrolled a total of 16 consecutive patients, thus probably being 
underpowered.[34]. Wahba et al conducted prospective comparative study enrolling 40 
patients scheduled for elective cardiac surgery. PFA-100 ® and Hepcon HMS were compared 
in assessment of bleeding prediction to each other and with conventional lab  and operative 
data[35]. Preoperative PFA-100 ® closing time significantly correlated to total blood loss 
(r=0.41, p=0.022). Contrary to, preoperative Hepcon ® HMS data failed to correlate with 
postoperative blood loss (r=0.18, p=0.37)[35]. Although PFA-100® was found to 
significantly correlate to CTD , authors considered study to be negative since the correlation 
of blood loss with PFA-100 ® was not greater than with the results of  conventional and 
simple coagulation tests such as platelet count, D-dimers or duration of CPB[35]. Using PFA-
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100 ® device Slaughter et al conducted prospective study on 58 adults undergoing primary 
elective CABG[36]. Collagen/ADP closure time, measured both pre-operatively and 15 min 
after protamine administration failed to correlate with either 6 or 12 hours CTD. 
Collagen/ADP closure time at 15 minutes after protamine administration did not significantly 
differ between patients transfused or not transfused with platelet concentrate [36]. In detecting 
“bleeders”, PFA–100
®
 was found to have positive and negative predictive values of 18% and 
98% [36]. Those results direct authors to conclude that PFA-100
®
 may be useful in 
identifying patients unlikely to benefit from platelet transfusion , therefore help to avoid 
unnecessary platelet transfusion [36]. Forestier et al compared PFA-100
® 
and Hemostatus 
point-of-care platelet function tests in study cohort divided into two groups with respect to 
excessive bleeding presence following arrival to intensive care unit[37]. Patients were not 
exposed to APT at least for 7 days prior to surgery, and additionally were excluded from 
study if diffuse bleeding occurred without identified surgical source of bleeding after 
protamine administration[37]. Platelet function tests were performed following arrival to ICU, 
either when excessive hemorrhage was diagnosed or after 3 hours following arrival to 
ICU[37]. There were no significant differences in Hemostatus and PFA-100
®
 parameter 
values between “bleeders” and “non-bleeders” [37]. In addition to, both Hemostatus and PFA-
100
®
 parameter values did not correlate with amount of CTD [37]. Based on observed overall 
lack of correlation between platelet function tests and CTD, authors suggested that these 
platelet function assays should not be routinely used in cardiac surgical patients[37]. 
However, they presumed that these tests would be more efficient for patients considered to be 
at higher risk of bleeding[37]. Fattorutto et al conducted prospective study with aim to 
evaluate if PFA-100
®
 predicts postoperative blood loss[38]. PFA-100
®
 failed to predict 
postoperative bleeding[38]. Several issues has to be discussed in this paper by Fattorutto et 
al[38]. Study recruited 70 patients with normal coagulation function and platelet count in 
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whom APT had been withdrawn for at least 5 days before surgery. It is obvious that study was 
performed in non-bleeding patients group since mean total CTD was 495±301 mL and the 
incidence of excessive CTD was found to be only 6%. Therefore, one may expect that almost 
every test must fail to predict excessive bleeding in patients that are not bleeding excessively. 
Cammerer et al conducted prospective study enrolling 255 patients with aim to evaluate 
weather modified rotational thromboelastometry (ROTEG
TM
) and platelet function analyzer 
PFA-100
®
 were predictive of postoperative blood loss [39]. ROTEG
TM
 and PFA-100
®
 tests 
performed after CPB were significantly different between patient groups divided with the 
respect to the presence of excessive postoperative blood loss [39]. In contrast to, preoperative 
ROTEG
TM 
findings failed to predict postoperative blood loss [39]. Noteworthy, abnormal 
bleeding was defined in two ways [39], and the definition of excessive bleeding influenced 
the ability of PFA-100
®
 to distinguish patients according to bleeding diathesis [39]. While 
preoperative PFA-100
®
 showed significant differences between patient groups divided 
according to extent of 750 mL of 6 hrs postoperative bleeding, the differences were not 
present if patients were divided according to study protocol data (upper quartile of blood loss 
in respective cohort group)[39]. Finally, reported high negative predictive values suggest the 
role of point-of-care tests in bleeding prediction and decision making process by identifying 
patients who will tend to not bleed caused by hemostatic disorder , which direct management 
of possible bleeding to surgical treatment[39].  
Gerrah et al investigated the possibility of bleeding prediction using cone and 
plate(let) analyzer (CPA , Impact-R , DiaMed, Cressier/Morat, Switzerland) in cardiac 
surgery patients[40]. The major advantage of CPA over the rest of platelet function analyzers 
is the fact that CPA measures platelet function as well as the interaction between platelets and 
von Willebrand factor (vWF).  Patients with pathologic values of CPA parameters had both 
the higher incidence of excessive postoperative bleeding (> 965 mL , 44% vs. 0%),  as well as 
14 
 
higher amount of blood loss (908 +/- 322 mL vs. 337 +/- 78 mL) indicating preoperative 
platelet function as assessed with CPA as an independent risk factor determining adverse 
bleeding events [40]. 
Solomon et al [41] used two point-of-care platelet function analyzers (Multiple 
electrode aggregometry, Multiplate (MEA), Verum Diagnostica GmbH and Dynabyte 
Informationssysteme GmbH, Munich, Germany); and cone and plate (let) analyzer (CPA) – 
Impact R (DiaMed, Cressier/Morat, Switzerland)) with aim to investigate which test is 
superior in preoperative assessment of platelet concentrate transfusion. MEA was found to be 
more useful in predicting patients prone to intraoperative platelet concentrate transfusion [41]. 
Rahe-Meyer et al provided valuable contribution to evaluation of relationship between MEA 
results and bleeding extent as well as platelet concentrates transfusion[42]. MEA findings 
were divided into tertiles of value distribution [42]. There were no significant differences 
between the low and the high tertile of MEA tests with respect to 24-h drainage volume [42]. 
Pre-operative MEA ADP and COL tests were predictive of platelet concentrate 
transfusion[42]. Authors concluded that platelet function assay offers the possibility of an 
early estimation of the risk of transfusion [42]. In our opinion, this contribution was very 
valuable since prediction of platelet concentrate transfusion allows for timely hemostatic 
intervention. In this study,  attending clinicians were blinded for platelet function tests results, 
however, platelet concentrate administration was a first line therapy in patients considered for 
hemostatic interventions with known recent exposure to APT. However, the question whether 
the application of MEA may reduce the amount of platelet concentrate transfusion by targeted 
administration remained uncertain [42]. Reece et al [43] conducted study with aim to 
determine whether platelet function disorder as assessed by MEA would predict excessive 
bleeding and blood transfusion. The study conducted in prospective, clinician blinded fashion 
enrolled 44 patients. Although CTD was measured hourly for 12 hours and until chest tube 
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removal, authors did not report correlations between CTD extent and platelet function test 
values [43]. MEA showed significant differences between transfused and non-transfused 
patients during chest closure , ADP test (18 U vs 29 U; p=0.01) and TRAP test (65U vs 88U, 
p=0.01), respectively [43]. Moreover, authors performed ROC[44] analysis with aim to detect 
the cut-of value of MEA tests that suggest transfusion requirements [43]. Measured ROC area 
under curve areas were small (0.691 for TRAP test and 0.674 for ADP test) which 
consequently results in weak prediction models of ROC analysis [43]. Threshold effect for 
transfusion outcome was 100 U (TRAP test) and 31 U (ADP test) with specificity values 1 for 
both tests, but low sensitivity values of 0.333 and 0.267, respectively [43]. However, high 
specificity for observed cut-of values allows for determination of patients who will probably 
be free of transfusion [43]. Another study investigating association between MEA and 
postoperative bleeding and platelet transfusion was conducted by Ranucci et al [45]. A total 
number of 87 patients with preoperatively administered thienopyridines were retrospectively 
analyzed [45]. ROC analysis was performed and ADP test value of 31 AUC was predictive of 
excessive bleeding with a sensitivity of 72% and a specificity of 66% [45]. High negative 
predictive value of 92% suggested the possible role of platelet function test in decision 
making algorithm by directing hemostatic management towards surgical hemostasis in cases 
of normal platelet function test values. Authors described positive relationship between ADP 
test and platelet transfusion, however this should be interpreted cautiously since the study was 
retrospective and ADP test value less than 40 AUC[45] influenced hemostatic management in 
respective study cohort. Petricevic et al investigated the possibility of excessive bleeding 
prediction using MEA in 211 patients following CABG [46]. MEA was performed 
preoperatively using ASA sensitive (ASPI test) and thienopyridines sensitive (ADP test) 
platelet function tests[46]. Both ASPI (p=0.014) and ADP (p=0.003) tests correlated 
significantly with 24 h CTD [46] and ROC analysis found ASPI test value of <20 AUC , as 
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well as ADP test value of <73 AUC to be bleeder determinants[46]. The same research group 
conducted another prospective study  recruiting 148 patients who required elective cardiac 
surgery[47]. In this study, use of MEA was supplemented with rotational thromboelastometry 
(ROTEM) and tests were performed simultaneously in three perioperative time points. The 
important finding of this study was that the strongest correlations between MEA and ROTEM 
were observed at third time point of blood sampling (after protamine administration)[47]. 
Thus, not only preexisting platelet function (influenced by inherent activity and/or APT) , but 
platelet function altered by CPB and surgical trauma itself , may more precisely reflect 
bleeding tendency[47]. Weber et al conducted, to our best knowledge, the only one 
prospective, randomized clinical trial evaluating the efficacy of point-of-care devices in 
coagulopathic cardiac surgery patients[48]. Two hemostatic transfusion managements were 
compared: control group was managed using transfusion algorithm based on conventional 
laboratory findings, while transfusion management in interventional group was directed 
according to findings of two point-of-care devices (TEM and MEA) [48].  Study was 
terminated earlier because the planned interim analysis of the primary outcome (the number 
of units of packed red blood cells administered in the first postoperative 24 hrs) revealed 
significant group differences favoring interventional group[48]. In addition to, patients in the 
conventional group lost more blood in early postoperative phase [48]. We may conclude that 
point-of-care directed transfusion management resulted with targeted and reduced amount of 
allogeneic products transfused followed by lower extent of postoperative bleeding. Recently, 
Schimmer et al [49] published retrospective study[49] with aim to find out whether platelet 
function tests results reflected postoperative bleeding extent or transfusion requirements[49]. 
Put briefly, decreased preoperative MEA platelet function test values were associated with 
increase in postoperative blood transfusion requirements[49]. Neither of MEA tests 
performed preoperatively correlated with postoperative bleeding extent [49]. Di Dedda et al 
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published retrospective analysis of prospectively collected data[50] with aim to assess the 
platelet inhibitory response to thienopyridines, to assess the dynamics of platelet function 
after thienopiridines cessation and finally to evaluate the relationship between platelet 
function test values and bleeding and transfusion outcomes[50]. Using repetitive 
measurements of MEA ADP test , authors have found that patients with adequate preoperative 
platelet inhibitory effect revealed with thienopyridines have the mean ADP test increase of 12 
U/day following drug discontinuation[50]. Those data are very valuable since authors 
described platelet recovery dynamics following thienopyridines discontinuation[50]. The 
same research group (SCORE research group) previously defined cut-off value of ADP test 
31 AUC to delineate excessive bleeding tendency after cardiac surgical procedures[45]. 
Therefore, known cut-of value of 31 AUC, together with expected daily recovery dynamics of 
12 AUC per day, allows for tailored preoperative management of thienopyridines 
discontinuation. On the other hand, if patient on thienopiridines treatment has value of ADP 
test above cut-of, it seems reasonable to proceed with surgery without thienopiridines free 
interval of 5 days as proposed by guidelines[29]. Considering bleeding outcomes, the last 
ADP test value prior to surgery was significantly associated with postoperative bleeding 
(p=0.002) [29]. Finally authors concluded that platelet function testing immediately prior to 
surgery is determinant of postoperative bleeding and requirement for platelet concentrates 
transfusions[50]. Since the study was retrospective analysis of prospectively collected data, 
results (especially for platelet concentrate transfusion in thienopyridines responsive patients 
subgroup) should be interpreted cautiously because ADP test value was a part of decision 
making process thus creating bias[29].  
Alstrom et al investigated platelet function in patients undergoing CABG with recent 
preoperative ASA and CLO exposure (within 3 days)[51] using flow cytometry including 
VASP phosphorylation and two bedside suitable point-of-care analyzers, VerifyNow System 
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(Accumetrics, San Diego, Calif) and the TEG Platelet Mapping device[51]. The authors 
sough to evaluate whether preoperatively performed assessment of platelet function could 
predict the risk of bleeding and transfusion requirements following cardiac surgical 
procedures [51]. VerifyNowP2Y12 was the only platelet function assay that showed 
significant correlations with total blood loss (Spearman’s Rho 0.29, p=0.03) and the total 
number of red blood cell transfusions (r=0.43, p<0.01). Notably, none of the above mentioned 
assays predicted transfusion of platelet concentrate and fresh frozen plasma [51]. 
Interestingly, TEG PlateletMapping-MAADP test revealed Spearman’s Rho of only 0.01 in 
correlation with total blood loss[51] which was substantially opposite than findings reported 
by Presiman et al[25] who found the same device to be of clinical usefulness in prediction of 
postoperative bleeding[25]. Very recent study by Rosengart et al[52] evaluated the ability of 
platelet function testing to identify CABG patients at increased risk for bleeding and 
transfusion outcomes[52]. Study enrolled patients who underwent isolated CABG with 
documented preoperative CLO administration[52]. Preoperative platelet function was assayed 
within 24 hours of surgery by measuring P2Y12 receptor blockade with the VerifyNow 
system (Accumetrics, San Diego, Calif). Patients were divided according to presence of 
higher platelet reactivity units (PRU) (≥237 PRU) or lower platelet reactivity (<236 PRU). 
Lower PRU subgroup was more likely to bleed excessively (OR 1.99; 95% CI, 1.02-3.88, 
p=0.04; c-index 0.584) and to be transfused with procoagulant blood components (OR, 2.33; 
95% CI, 1.2-4.54; p=0.01; c-index, 0.603). In addition to, authors performed exploratory 
analysis in which patients were divided into three groups according to PRU value distribution 
(high (>290 PRU), intermediate (200-290 PRU) and low (<200 PRU). Odds of having 
excessive CTD and procoagulant blood component increased significantly as an incremental 
function of exploratory patients grouping according to PRU value distribution (OR, 2.26; 
p<0.001). Authors concluded that the risks of bleeding and transfusion outcomes can be easily 
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predicted using point-of-care platelet function testing[52] although results should be 
interpreted cautiously due to retrospective study design.  
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DISCUSSION 
Bleeding in cardiac surgery is multicausal, and several factors such as comorbidities, 
preoperative medications, surgical technique and perioperative hemostatic management as 
well as the complexity of surgical procedure influence the extent of postoperative blood loss. 
Thus, it seems that due to multicausality in pathogenesis of excessive bleeding following 
cardiac surgery, attempts to create a universal hemostatic agent will certainly fail. 
Several platelet function assays are available, and paucity of data exists regarding its clinical 
utility, but different assays and different study designs hamper the meaningful comparisons. 
Generally, platelet function testing cutoffs used among different centers are derived from 
manufacturers, on the clinical leaders’ opinion or are based on the retrospective/prospective 
studies conducted in respective centers in order to delineate clinical outcomes (bleeding, 
transfusion and adverse clinical outcomes). However, there is shortage of generally applicable 
cutoffs that could be reproduced and implemented by worldwide centers. This shortage arises 
from the lack of prospective multicentric trials that would firstly define the cutoffs for 
bleeding events, transfusion requirements as well as for ischemic events. 
Put briefly, to be clinically useful, a platelet function assay must fulfill several criteria: 1) the 
platelet function test should be validated in large number of specific patient groups. 
Stratification of patients according to the respective risks should be feasible, and if possible, 
platelet function assays should provide “safety window” range of values that should be 
targeted when deciding on preoperative APT administration and/or discontinuation, 2) the 
assay should be bedside suitable, user friendly and should have as short as possible 
“turnaround time” (time from blood sampling to obtaining results) in order to provide timely 
detection of risk for bleeding and subsequent risk of transfusion which would in turn allow for 
timely hemostatic interventions. Such an approach requires studies to be conducted in 
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prospective fashion to determine whether the platelet function test can identify patients at risk 
for a particular adverse outcome (excessive bleeding , excessive allogeneic blood products 
transfusion requirements, adverse ischemic events ) using ROC curve[44] analysis. 
When assessing the role of platelet function tests for prediction of bleeding and 
transfusion outcomes some methodological considerations should be addressed. Different 
study designs were used in different investigations with aim to evaluate association between 
platelet function test results and bleeding extent and transfusion requirements. 
Prospective observational studies are capable to provide the most accurate cutoffs with 
sensitivity and specificity that are best possible in clinical settings. Experimental study setting 
is not ethically acceptable. For example, although prospective studies using platelet function 
tests should be “clinician blinded”, patients receive hemostatic therapy according to regular 
clinical protocols and procoagulant blood components administration certainly attenuate 
correlations coefficient between measured platelet function test values and observed bleeding 
extent. Secondly, cutoffs that are defined in prospective observational studies using ROC 
analyses should be tested through prospective randomized studies to assess the safety, 
efficacy and cost-effectiveness of customized approaches based on platelet function testing 
results. Generally, various platelet function testing provide a high negative predictive 
values[39] which in turn may allow for (1) a reduction in the number of days that patients 
with a preoperatively administered dual APT are off antiplatelet agents, as suggested by the 
current guidelines[29,30] and for (2) reduction of procoagulant components transfusion rate. 
Such an approach would lead to determination of the optimal safe period from discontinuation 
of APT to surgery for the individual patient and would minimize unnecessary transfusions. 
Again, such a tailored approach should be evaluated through prospective randomized clinical 
outcome evaluating trials.  
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As previously mentioned, prospective studies are the most suitable for assessment of bleeding 
risks and transfusion requirements. However, there are several retrospective studies 
addressing same issue[45,49,50,52]. The major drawback of retrospective studies is the fact 
that evaluated platelet function testing was used in clinical decision making process. Although 
such studies have often high number of patients from databases, it is obvious that observed 
associations are in certain degree distorted by the fact that platelet function tests were used in 
clinical decision making process, thus probably creating bias in estimations of relationship 
between test results and both bleeding extent and transfusion requirements.   
When discontinuing preoperative APT, one should be aware that some proportion of 
those patients is resistant to APT (have high degree of residual platelet reactivity despite 
appropriate treatment). Our working group recently found 31.3% of patients to be ASA 
resistant preoperatively[53]. Therefore, ASA discontinuation in this subgroup of patients may 
lead to further increase of platelet reactivity and pose patients to proclivity to ischemic events. 
In addition to, resistance to CLO therapy , increasingly administered antiplatelet drug in 
preoperative phase may be present in range between 25% -60%[54]. Therefore, use of point-
of-care platelet function analyzers may prevent not only bleeding events but also ischemic 
events by detecting those patients who experience high on-treatment platelet reactivity who 
might benefit from late or no APT discontinuation. Too early APT discontinuation may lead 
to onset of platelet hyperactivity [55,56] and subsequently cause adverse ischemic events in 
preoperative phase. Finally, use of platelet function analyzers may provide dual benefit in 
terms of prevention of both bleeding and ischemic events. 
Literature review revealed both positive and negative studies regarding association 
between platelet function analyzer findings and both bleeding outcomes and transfusion 
requirements.  Heterogeneity of devices and variability in study settings hampers evidence 
and makes it somehow hard to pool the findings and make strong conclusions. Firstly, there is 
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no generally accepted definition of excessive bleeding and observed definitions vary widely 
across literature (Table 1). Standardized definition of excessive bleeding is necessitating. We 
propose measurement of CTD in first 24 hours and the extent of CTD should be divided by 
patient’s weight. Patients should be characterized as bleeders if their 24 h CTD (ml/kg) 
exceeds 75
th
 percentile of distribution in predefined sample of patients. Such a definition 
makes the most reliable correlation, and is not distorted to different anthropometric measures, 
perfusionistic, surgical and anesthetic techniques. Such an approach dichotomizes bleeding 
outcome. The alternative approach would be to correlate platelet function test findings with 
CTD as expressed in form of continuous variable. Any significant correlations should further 
be tested for accuracy via ROC analysis[44]. In this way it would be possible to reach the best 
sensitivity/specificity ratio as well as positive and negative predictive values. Drawbacks of 
the CTD quantification were briefly discussed by Ti et al[9]. One should be aware that blood 
loss measured as CTD consists of a mixture of fluids, including actual blood loss, serous 
drainage and fluid left in the pleural cavities. Furthermore, bleeding is consisted of two types 
depending on the origin of bleeding: (1) bleeding due to hemostatic disorder including platelet 
dysfunction and (2) bleeding due to surgical issues.  
Treatment options of hemorrhage in cardiac surgery are continuously evolving. 
Recently, Gorlinger et al provided comprehensive insight into this issue[57]. It is however 
obvious that appropriate hemostatic management in cardiac surgery patients should be 
consisted of bundle of protective strategies to prevent and treat excessive bleeding such as:  
1) Preoperative bleeding risk stratification , based mainly on detection of patients who 
have weak platelet function thus proclivity to excessive bleeding. This part is largely 
elaborated in present review article. 
24 
 
2) Intraoperative transfusion management based on point-of-care hemostatic tests. 
There is evidence for efficacy of such a transfusion management based on tests for 
assessments of viscoelastic blood properties (ROTEM) and platelet function tests[48]. 
Different treatment modalities are available depending on possibilities of each cardiac surgery 
center. We propose algorithm for perioperative hemostatic management that we use at our 
center (Figure 1.). Such an algorithm provides a concept that may be applied generally and 
adjusted to different point-of-care hemostatic tests as well as different hemostatic treatment 
modalities available. 
 3) Surgical measures to achieve meticulous hemostasis 
Bleeding due to surgical issues should not be underestimated for two reasons: (1) it certainly 
affects the extent of CTD which was found to be independently associated with adverse 
outcomes after cardiac surgery[2,3] , and (2) more than 70% of patients undergoing re-
exploration for excessive bleeding have had bleeding vessel identified (surgical cause of 
bleeding)[4]. Surgeon performance may contribute significantly to such a complication. 
Biancari et al hypothesized that individual surgeons performance may contribute significantly 
to bleeding outcome [4]. Retrospective study on 2001 patients reported re-exploration for 
bleeding rate of 5.3% [4]. Of more importance rates of re-exploration varied between 1.4% 
and 11.7% (p<0.0001) according to different surgeons performing hemostasis [4]. 
Furthermore, variable of individual surgeon was found to be independent predictor for re-
exploration for excessive bleeding, as well as for CTD of ≥ 1600 mL [4]. Kim et al 
demonstrated that individual surgeon was found to be strongest factor associated with 
transfusion outcome in patients undergoing CABG with recent CLO exposure[58]. Therefore, 
meticulous surgical technique must be cornerstone on appropriate hemostatic management 
since individual surgeon’s skills may be important as much as the preoperative APT 
discontinuation management based on platelet function testing. Moreover, Loor et al [59] 
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developed and implemented a formal operative checklist to reduce technical reasons for 
postoperative bleeding[59]. Easily performed hemostasis checklist based on the most 
common sites of bleeding was developed[59]. Implementation of such bleeding checklist 
resulted in increased number of cases operated on between consecutive reoperations[59]. 
Therefore, in order to optimize bleeding outcomes, meticulous surgical technique along with 
checklist for bleeding should be inextricably included to perioperative APT administration 
management targeted after platelet function testing.  
In conclusion, appropriate perioperative hemostatic management should inevitably 
include bedside suitable point-of-care devices and hemostatic management should be based 
on goal-directed hemostatic therapy, so called “theranostic approach” [45,48,57,60-62]. Such 
an approach may reduce the rate of reexploration for bleeding from up to 75% [4] to 20% [48] 
, as recently described by Weber et al through prospective randomized trial [48]. Point-of-care 
guided hemostatic algorithm may reduce the rate of reexplorations due to hemostatic disorder 
and direct reexploration surgery dominantly to surgical cause of bleeding. The reduction of 
unnecessary as well as inefficient surgical reexplorations rate certainly may improve clinical 
outcome. There are a large number of studies dealing with prediction and prevention of 
excessive bleeding in cardiac surgery patients. Platelet function analyzers should definitely be 
included in modern hemostatic management with aim to frame safety therapeutic window 
(between bleeding and ischemic events). We suggest use of platelet function testing in 
perioperative setting of cardiac surgery patients. However, when using such devices, one 
should be aware of platelet function testing limitations in estimating risk for excessive 
bleeding and transfusion requirements. Such devices may not always provide accurate 
prediction of bleeding which can be easily explained by the fact that bleeding is consisted of 
both surgical bleeding and bleeding due to hemostatic disorder of which platelet function is 
only one part. In process of decision making based on point-of-care hemostatic tests one 
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should account with the possibility of excessive bleeding despite normal values of hemostatic 
tests. The reason for such a phenomenon may be the fact surgical hemostasis is not always as 
good as it should be, in particular in teaching hospitals. Meticulous surgical hemostasis must 
be performed in order to exclude surgical cause of bleeding. Procoagulant blood component 
administration should be targeted after both platelet function assay results and TEM/TEG 
results. Antifibrinolytics as well as DDAVP should be considered in cases where weak 
platelet function or high fibrinolysis index is detected using point-of-care devices. 
Multicausality in hemostatic disorders requires multidisciplinary and comprehensive approach 
in treatment.  “One size fits for all” approach in hemostatic management seems to be obsolete, 
and shift towards personalized approach using bedside suitable point-of-care devices in 
bleeding and transfusion requirements optimization is certainly required.  
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Figure Legends: 
Figure 1. Perioperative hemostatic management algorithm (TEG/TEM: 
thromboelastography/thromboelastometry) 
 PREOPERATIVE 
CONSIDERATIONS 
INTRAOPERATIVE 
CONSIDERATIONS 
POSTOPERATIVE 
CONSIDERATIONS 
ANTIPLATELET DRUGS ADMINISTERED PREOPERATIVELY 
„DRUG SPECIFIC“ PLATELET FUNCTION TESTING 
PRONOUNCED 
PLATELET INHIBITION 
HIGH „ON TREATMENT“ 
PLATELET REACTIVITY 
„DRUG SPECIFIC“ PLATELET FUNCTION TESTING 
ELECTIVE 
PROCEDURES 
„URGENT/EMERGENT“ 
PROCEDURES 
DELAY OF SURGERY UNTIL 
PLATELETS RECOVERY 
PROCEED TO SURGERY 
„URGENT/EMERGENT“ PROCEDURES : POSSIBILITY OF 
EXCESSIVE BLEEDING AND PROCOAGULANT BLOOD 
COMPONENTS TRANSFUSION REQUIREMENTS 
INTRAOPERATIVE BLEEDING - „WET SURGICAL FIELD“ 
YES NO 
CHEST CLOSURE 
TEG/TEM GUIDED 
TRANSFUSION OF 
PROCOAGULANT BLOOD 
COMPONENTS 
INTENSIVE CARE UNIT 
EXCESSIVE CHEST TUBE DRAINAGE 
YES NO 
REPEAT TEG/TEM GUIDED 
TRANSFUSION OF 
PROCOAGULANT BLOOD 
COMPONENTS 
HEMOSTATIC DISORDER 
YES NO SURGICAL REEXPLORATION 
AUTHO
R YEAR 
TYPE OF 
STUDY 
ANTITHROMBO
TIC 
MEDICATIONS 
MANAGEMENT 
PLATELET 
FUNCTION 
TEST 
RESULTS 
USED TO 
GUIDE 
HEMOSTATI
C 
MANAGEME
NT 
STUDY 
COHORT 
PLATELET 
FUNCTION TEST 
TIMING OF 
PLATELET 
FUNCTION 
TESTING 
DEFINITION 
AND/OR 
INCIDENCE 
OF 
EXCESSIVE 
BLEEDING 
BLEEDING 
OUTCOME 
TRANSFUSIO
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Lennon et 
al, 2004 
Prospective 
observationa
l study 
patients who had 
received clopidogrel 
within week before 
surgery were 
excluded ; patients 
had taken aspirin up 
to a variable interval 
before surgery 
no 
50 CABG 
and valve 
surgery 
patients 
Plateletworks 
(Helena 
Laboratories, 
Beaumont, TX) 
before the 
commencement of 
anesthesia and on 
completion of 
surgery 
not reported 
Correlations with 
CTD were non-
significant both 
pre- (r=0.07, 
p=0.58) and post-
operatively 
(r=0.14, p=0.34) 
not reported 
Despotis 
et al, 
1996 
Prospective 
observationa
l study 
aspirin 67 patients ; 
heparin 42 patients ; 
warfarin 9 patients 
(within 1 week 
before surgery) 
no 
150 
patients 
undergoing 
cardiac 
surgery 
Platelet-activated 
clotting test (PACT) 
(Hemostatus ® ; 
Medtronic, Inc., 
Parker, CO) 
1) baseline (before 
anesthesia 
induction) ; 2) CPB 
(shortly before 
discontinuation of 
CPB) ; 3) post CPB 
(after 
heparin/protamine 
neutralization) ; 4) 
after arrival in the 
ICU 
excessive 
microvascular 
bleeding was 
defined as 
diffuse 
bleeding from 
the surgical site 
without an 
identifiable 
surgical source 
Excessive blood 
loss was 
successfully 
predicted 
(Significant 
correlations with 
CTD). 
not reported 
Ereth et 
al, 1997 
Prospective 
observationa
l study 
not reported no 
200 
patients 
undergoing 
cardiac 
surgery 
PACT (Hemostatus 
® ; Medtronic, Inc., 
Parker, CO) 1) after induction of 
anesthesia ; 2) 40 
min after initiation 
of cardiopulmonary 
bypass ; 3) 20-40 
min after protamine 
administration 
more than 200 
mL/h (or 100 
mL/h) of CTD 
in the first 4 
hours in the 
ICU 
 
No correlation 
between 
transfusion 
requirements and 
post-protamine 
PACT values 
Thromboelastograph
y (TEG, 
Haemoscope Corp., 
Glenview, IL) 
The postprotamine 
TEG MA also 
correlated with the 
4 hour CTD (r=-
0.32, p=0.003) 
not reported 
Ereth et 
al, 1998 
Prospective 
observationa
l study 
not reported no 
100 
patients 
undergoing 
cardiac 
surgery 
PACT (Hemostatus 
® ; Medtronic, Inc., 
Parker, CO) 
within 1 h after 
patient's arrival to 
the ICU 
The two 
disease states 
of bleeding 
after CPB were 
determined by 
> an average of 
100 ml/h and 
200 ml/h CTD 
in the first 4 h 
in the ICU 
None of PACT 
values correlated 
with CTD 
not reported 
Wahba et 
al, 1998 
Prospective 
observationa
l study 
patients on APT less 
than 10 days prior to 
surgery were 
excluded 
no 
40 patients 
undergoing 
cardiac 
surgery 
PFA - 100 ® (DADE 
Diagnostika, 
Unterschleissheim, 
Germany) 1) during anesthesia 
before institution of 
CPB and 2) at 
completion of 
surgery 
not reported ; 
CTD presented 
as a continuous 
variable 
Preoperative PFA-
100 ® closing time 
significantly 
correlated with 
CTD (r=0.41, 
p=0.022). 
not reported 
PACT 
(Hepcon/Hemostatus 
™ , Medtronic, 
Dusseldorf, 
Germany)  
Hepcon HMS did 
not correlate with 
CTD (r=0.18, 
p=0.37) 
Dietrich 
et al, 
1998 
Prospective 
observationa
l study 
patients had not 
received aspirin for 
at least 10 days 
no 
16 patients 
undergoing 
CABG 
PFA - 100 ® ; Dade, 
Miami, FL, USA 
1) after intubation ; 
2) 15 min after 
heparin/protamine 
not reported ; 
CTD presented 
as a continuous 
Only TEG-MA 
performed 
postoperatively 
not reported 
Impedance 
aggregometry 
(Chronolog, 
Havertown, PA, 
USA) 
reversal ; 3) three 
hours following 
admission to ICU 
variable correlated 
significantly with 
CTD 
TEG - 
Thromboelastograph 
D (Hellige , Freiburg 
, Germany) 
Platelet function-
PAF test (PFT, 
Medtronic, Parker, 
CO, USA) 
Slaughter 
et al, 
2001 
Prospective 
observationa
l study 
preoperative 
treatment with 
platelet glycoprotein 
receptor inhibitors, 
but not aspirin was 
considered as 
exclusion criteria 
no 
58 patients 
undergoing 
CABG 
PFA - 100 ® (Dade-
Behring Inc., Miami, 
FL, USA) 
1) preoperatively ; 
2) 5 min after 
heparin 
administration ; 3) 5 
min after initiation 
of CPB ; 4) 15 min 
after protamine 
administration 
cumulative 6h 
CTD exceeding 
646 ml/6h 
Non-significant 
correlations were 
detected between 
PFA - 100 ®  and 
CTD. 
Non-significant 
differences in 
collagen/ADP 
closure times (15 
min after 
protamine 
administration) 
between patients 
transfused and 
not transfused 
with PC 
Forestier 
et al, 
2002 
Prospective 
observationa
l study 
patients who had 
taken APT within 7 
days of the surgery, 
and those on heparin 
or anticoagulant 
therapy were 
excluded 
no 
45 patients 
undergoing 
cardiac 
surgery 
PFA - 100 ® (Dade-
Behring Inc., Miami, 
FL, USA) 1) on arrival in the 
ICU for all patients 
; 2) when excessive 
bleeding was 
diagnosed or after 3 
h in the ICU 
CTD 
>1ml/kg/h for 
at least 1 h 
during the first 
6 h after 
surgery 
Platelet function 
testing devices 
failed to correlate 
with CTD 
not reported 
PACT 
(Hepcon/Hemostatus 
™ , Medtronic, 
Rueil-Malmaison, 
France)  
PAP-4 
aggregometer; 
(BIO/DATA 
Corporation , Paris, 
France) 
Fattorutto 
et al, 
2003 
Prospective 
observationa
l study 
APT withdrawn for 
at least five days 
before surgery 
no 
70 patients 
undergoing 
cardiac 
surgery 
PFA - 100 ® (Dade-
Behring Inc., Miami, 
FL, USA) 
1) before CPB ; 2) 
after protamine-
induced heparin 
neutralization 
excessive CTD 
was defined as 
> 200 ml for 
two successive 
hours 
The pre-CPB 
CECT 
measurement 
correlated weakly 
with first- and 
second-hour CTD 
(r=0.32, p=0.01 
and r=0.34, 
p=0.01, 
respectively) 
not reported 
Cammere
r et al, 
2003 
Prospective 
observationa
l study 
41% patients 
received aspirin 
within 5 days before 
surgery ; 6% 
received 
ticlopidine/clopidogr
el until surgery ; 6% 
received coumadine 
until surgery 
no 
255 
patients 
undergoing 
cardiac 
surgery 
PFA-100 ™ (Dade 
Behring, 
Schwalbach, 
Germany) 
1) directly after the 
induction of 
anesthesia ; 2) 
during CPB after 
rewarming ; 3) 15 
min after protamine 
administration 
Abnormal 
bleeding: 1) 
CTD 750 
ml/6h; 2) CTD 
exceeding 75th 
percentile (500 
ml/6h 
postoperatively
) 
Solely the 
measurements after 
CPB showed 
significantly 
different values of 
both ROTEG and 
PFA between 
patients divided 
with respect to 
excessive CTD 
presence 
not reported 
Thromboelastograph
y - ROTEG ™ 
(Pentapharm, 
Munich, Germany) 
Poston et 
al, 2005 
Prospective 
observationa
l study 
preoperative aspirin 
was continued 
through the date of 
surgery 
no 
76 patients 
undergoing 
off-pump 
CABG 
TEG (Haemoscope 
Corporation, Niles, 
IL, USA) 
1) prior to skin 
incision ; 2) 
Immediately after 
skin closure 
24h CTD >800 
mL 
Perioperative 
decline in platelet 
function as 
assessed by WBA 
correlated with 
intraoperative 
blood loss 
(R=0.42, p<0.05), 
Perioperative 
decline in TEG-
MA significantly 
not reported 
Whole blood 
aggregometry 
(Chronolog , 
Havertown, 
Pennsylvania) 
correlated with 24 
hour hemoglobin 
loss (r=0.45, 
p<0.05)  
Carrol et 
al, 2006 
Prospective 
observationa
l study 
patients on APT 
were excluded 
no 75 patients 
TEG (Haemoscope 
Corporation, Niles, 
IL, USA) 
1) before heparin 
administration ; 2) 
15 minutes after 
heparin reversal 
with protamine ; 3) 
one hour post 
operation 
Bleeding 
assessment by 
observer 
agreement: not 
bleeding, 
oozing or 
excessive 
bleeding 
None of platelet 
function test 
parameters 
significantly 
correlated with 
bleeding 
not reported 
Preisman 
et al, 
2010 
Prospective 
observationa
l study 
57 patients were 
exposed to aspirin ; 
34 patients were 
exposed to 
clopidogrel 
preoperatively 
no 
59 patients 
undergoing 
CABG 
TEG (Haemoscope 
Corporation, Niles, 
IL, USA) platelet 
mapping with 
determination of the 
tensile strength of 
the platelet-fibrin 
clot induced by ADP 
(MAadp) or 
arachidonic acid 
(MAaa) 
prior to induction of 
anesthesia 
cluster analysis 
revealed two 
groups of 
patients with 
respect to 
bleeding 
tendency. CTD 
was 
significantly 
higher in 
bleeding group 
(1216 ± 310 
mL vs. 
576±105mL) 
MAadp parameter 
was the only TEG 
parameter that 
significantly 
predicted bleeding 
tendency 
(p=0.004).  
Significant 
correlation 
existed between 
the use of PC 
and MAadp  in 
patients with 
bleeding 
tendency (Rho=-
0.75, p=0.02) 
Kwak et 
al, 2010 
Prospective 
observationa
l study 
patients were 
preoperatively 
exposed to aspirin 
and clopidogrel 
no 
100 
patients 
undergoing 
off-pump 
CABG 
TEG (Haemoscope 
Corporation, Niles, 
IL, USA) platelet 
mapping (MAadp) 
immediately before 
the induction of 
anesthesia 
>200 mL/h in 
two 
consecutive 
hours 
Patients with the 
most pronounced 
platelet inhibition 
percentage had a 
significantly 
greater amount of 
post-operative 
CTD 
Patients with the 
most pronounced 
platelet 
inhibition were 
more frequently 
transfused with 
PRBSs and FFP. 
ROC analysis 
defined cutoff 
value for 
transfusion 
requirements 
(70% platelet 
inhibitory 
response to 
clopidogrel) 
Weitzel et 
al, 2012 
Prospective 
observationa
l study 
Patients on aspirin 
were included but 
exposure to 
clopidogrel was 
exclusion criterion 
not for platelet 
mapping, but 
standard TEG 
was used as a 
target for 
transfusion 
administration 
40 patients 
undergoing 
cardiac 
surgery 
TEG (Haemoscope 
Corp, Niles, IL, 
USA) , platelet 
mapping 
(MAcollagen, 
MAadp and MAaa) 
pre- and post-CPB 
>1000mL/24h 
CTD 
pre- and post-CPB 
Macollagen and 
pre-Maaa showed 
significant 
correlation with 
24-h CTD 
not reported 
Mahla et 
al, 2012 
Prospective 
interventiona
l, single 
center, 
unblinded 
study 
patients with 
background aspirin 
with/without 
clopidogrel 
treatment 
Yes (timing of 
surgery in 
clopidogrel 
treated patients 
was tailored 
after TEG MA 
results) 
180 
patients 
undergoing 
elective 
CABG 
TEG (Haemonetics 
Corporation 
Braintree, MA) 
platelet mapping  
(MAadp and MAaa)  
preoperative period  not reported 
There was no 
difference in CTD 
between 
clopidogrel-treated 
and clopidogrel-
naive patients 
No differences in 
the total amount 
of PRBCs 
transfused to 
clopidogrel-
treated patients 
as compared 
with clopidogrel-
naive patients 
(p=0.540) 
Gerrah et 
al, 2006 
Prospective 
observationa
l study 
2 (6%) patients were 
exposed to aspirin 
preoperatively 
no 
32 patients 
undergoing 
cardiac 
surgery 
Cone and Plate(let) 
Analyzer, CPA, 
Impact-R (Diamed, 
Cressier/Morat, 
Switzerland) 
1) during induction 
of anesthesia ; 2) 
immediately after 
sternotomy ; 3) 10 
min after heparin 
injection ; 4) 10 and 
30 min after 
establishment of 
CPB ; 5) after 
discontinuation of 
CPB ; 6) 10 min 
after protamine 
injection ; 7) at the 
end of the operation 
severe blood 
loss > 965 mL 
of CTD 
According to 
multivariate 
analysis 
postoperative 
bleeding was found 
to be significantly 
and linearly 
dependent of the 
preoperative 
platelet function by 
average size and 
surface coverage 
(p=0.003 and 
0.001, 
respectively). 
No difference 
was found 
between the 
percentage of 
patients who 
received 
transfusions and 
preoperative 
CPA parameters 
Rahe-
Meyer et 
al, 2009 
Prospective 
observationa
l study 
aspirin discontinued 
for more than 4 days 
in 55 patients and 
clopidogrel 
discontinued for at 
least one week 
before surgery in 58 
patients 
no 
60 patients 
undergoing 
cardiac 
surgery 
Multiplate ® , 
Dynabyte Medical , 
Munich , Germany 
1) before induction 
of anesthesia  and 
2) at the end of 
operation 
not reported 
No significant 
differences 
between the low 
and the high tertile 
of platelet function 
were noted with 
respect to 24-hour 
CTD 
Patients with 
Multiplate 
results within 
lower tertile 
received 
significantly 
more PC 
transfusion 
(Preoperative 
tests: p=0.006 
for the ADP test 
and p=0.03 for 
the COL test ; 
Postoperative 
tests: p=0.028 
for the ADP 
test).  
Solomon 
et al, 
2010 
Prospective 
observationa
l study 
5 (10%) of patients 
exposed to aspirin 
within 3 days of 
surgery 
no 
50 
consecutiv
e CABG 
and AVS 
patients 
Multiplate ®, 
Dynabyte Medical , 
Munich , Germany 
before induction of 
the anesthesia 
not reported not reported 
Multiplate ASPI, 
ADP and COL 
test significantly 
correlated with 
PC transfused 
intraoperatively 
Cone and Plate(let) 
Analyzer , CPA , 
Impact-R , Diamed, 
Cressier/Morat, 
Switzerland 
CPA parameters 
did not correlate 
significantly 
with transfusion 
parameters 
Reece et 
al, 2011 
Prospective 
observationa
l study 
7/44 patients 
exposed to aspirin ; 
1/44 to clopidogrel 
and 4/44 to aspirin 
and clopidogrel 
within 6 days before 
surgery 
no 
44 patients 
undergoing 
CABG 
Multiplate ® , 
Dynabyte Medical , 
Munich , Germany 
(ASPI test , ADP test 
, TRAP test) 
1) induction of 
anesthesia ; 2) 20 
min on cardiac 
bypass ; 3) chest 
closure ; 4 ) ICU 
arrival 
not reported not reported 
ADP (18 U vs. 
29 U; p=0.01) 
and TRAP (65 U 
vs. 88 U; 
p=0.01) tests 
performed 
during chest 
closure were 
significantly 
lower in 
transfused 
patients 
Ranucci 
et al, 
2011 
Retrospectiv
e analysis of 
prospectivel
y collected 
data 
patients were 
exposed to 
clopidogrel within 7 
days of surgery 
yes 
87 patients 
undergoing 
cardiac 
surgery 
Multiplate ® , 
Dynabyte Medical , 
Munich , Germany 
(ADP test , TRAP 
test) 
preoperatively 
≥800 ml/12 
hours CTD 
ADP test was 
independently 
associated with 
postoperative 
bleeding 
(Regression 
coefficient -0.47, 
p=0.007). ROC 
analysis revealed  
ADP test cut-off 
31 AUC to 
delineate excessive 
bleeding. 
Patients with 
ADP test AUC 
lower than 31 U 
had significantly 
higher rate of PC 
transfusion 
(p=0.044) 
Petricevic 
et al, 
2012 
Prospective 
observationa
l study 
patients were 
exposed to aspirin 
and/or clopidogrel 
no 
211 CABG 
patients 
Multiplate ® , 
Dynabyte Medical , 
Munich , Germany 
preoperatively 
24 hour CTD ≥ 
11.33 ml/kg 
Significant 
correlations 
between the ASPI 
test and ADP test 
with 24 h CTD 
were found. ROC 
delineated ASPI < 
20 AUC and 
ADP<73 AUC as a 
"bleeder" 
determinant 
ASPI , but not 
ADP test was 
significantly 
lower in a group 
of patients 
transfused with 
PRBC 
Webber 
et al, 
2012 
Prospective, 
randomized 
parallel-
group single 
center study 
preoperative APT, 
including aspirin, 
was ceased at least 6 
days before surgery 
yes 
100 
patients 
undergoing 
cardiac 
surgery 
Multiplate ®, 
Dynabyte Medical , 
Munich , Germany 
(ASPI test ,ADP test 
, TRAP test) 
intraoperatively not reported 
Patients in the 
conventional group 
lost more blood 
after admission to 
the ICU. However, 
there was no 
difference in 
reexploration rate. 
Compared with 
the conventional 
group, patients in 
the POC group 
were transfused 
less often with 
PC, FFP, rVIIa 
ROTEM ®, Tem 
International, 
Munich , Germany 
Schimme
r et al, 
2012 
Retrospectiv
e 
observationa
l clinical 
study 
Patients were 
exposed to APT 
yes 
223 adult 
cardiac 
surgical 
patients 
Multiplate ®, 
Dynabyte Medical , 
Munich , Germany 
(ADP test , ASPI 
test, TRAP test) 
1) beginning of 
anesthesia ; 2) 30 
min upon arrival on 
the ICU 
not reported 
Pathological values 
of ASPI, ADP and 
TRAP test values 
did not reflect 
higher 
postoperative 
CTD.  
ADP test value 
<534AU*min 
was associated 
with more PCs 
transfusion. 
TRAP test value 
<941 Au*min 
was associated 
with more RBC 
transfusion 
(p=0.02) and PC 
transfusion 
(p=0.02).  
Petricevic 
et al, 
2013 
Prospective 
observationa
l study 
patients were 
exposed to aspirin 
and/or clopidogrel 
preoperatively 
no 
148 
patients 
(elective 
cardiac 
surgery) 
Multiplate ®, 
Dynabyte Medical, 
Munich, Germany 
1) preoperatively; 
2) during CPB ; 3) 
after protamine 
administration 
24 hour CTD ≥ 
12.46 ml/kg 
ASPI , ADP , 
TRAP test 
significantly 
correlated to 24 
hour CTD not reported 
ROTEM ®, Tem 
International, 
Munich, Germany 
All TEM tests 
significantly 
correlated to 24 
hour CTD 
Di Dedda 
et al, 
2013 
Retrospectiv
e analysis of 
prospectivel
y collected 
data 
aspirin was not 
discontinued before 
surgery ; clopidogrel 
was discontinued 
within 7 days before 
surgery 
yes 
344 
patients 
undergoing 
cardiac 
operations 
Multiplate ®, 
Dynabyte Medical, 
Munich, Germany 
preoperatively not reported 
The last ADP test 
before the 
operation was 
significantly 
associated 
(p=0.002) with 
postoperative 
CTD. 
The last ADP 
test before the 
operation was 
significantly 
associated 
(p=0.001) with   
postoperative PC 
transfusions 
Alstrom 
et al, 
2009 
Prospective 
observationa
l study 
aspirin was 
continued until 
surgery ; clopidogrel 
was ceased within 
three days before 
surgery 
no 
60 patients 
undergoing 
CABG 
VerifyNow P2Y12 
test and Aspirin test 
(Accumetrics, San 
Diego, CA) 
1) before anesthesia 
; 2) after protamine 
not reported 
VerifyNow 
significantly 
correlated to CTD 
(r=0.29 , p=0.03) 
VerifyNow 
significantly 
correlated with a 
total number of 
PRBCs 
transfusions 
(r=0.43, p<0.01) 
TEG 5000 
Hemostasis Analyzer 
and PlateletMapping 
(Haemoscope 
Corporation, Niles, 
Illinois, USA) MAaa 
and MAadp 
parameters used. 
no significant 
correlations were 
observed for  TEG 
5000  (r=0.01, 
p=0.98) 
no significant 
correlations were 
observed  for  
TEG 5000 
(r=0.05, p=0.69) 
Rosengart 
et al, 
2013 
Retrospectiv
e analysis of 
prospectivel
y collected 
data 
54% of patients 
received clopidogrel 
preoperatively; 70% 
of patients received 
aspirin 
preoperatively 
yes 
276 
patients 
undergoing 
CABG 
VerifyNow P2Y12 
test (Accumetrics, 
San Diego, CA) 
preoperatively  
12 hours CTD 
> 437 mL 
Multivariate 
analysis showed 
that CTD alone 
was not 
significantly 
different between 
the higher- and 
lower-PRU groups 
(p=0.09). 
Multivariate 
analysis revealed 
patients with 
lower PRU to 
require 
procoagulant 
components 
transufsion (OR, 
2.82; 95% CI, 
1.39-5.73; 
p=0.0004; c-
index, 0.642) 
 
Table 1.  
Summary of the studies evaluating the relationship between platelet function test findings and bleeding as well as transfusion outcomes. 
List of abbreviations: ADP: Adenosine diphosphate induced aggregation; APT: Antiplatelet therapy; ASPI: Arachidonic acid induced aggregation; AUC: Area 
under the curve; AVS: Aortic valve surgery; CABG: Coronary artery bypass graft; CECT: Collagen/epinephrine closure time; CI: Confidence interval; COL: 
Collagen; CPA: Cone and platelet analyzer; CPB: Cardiopulmonary bypass; CTD: Chest tube drainage; FFP: Fresh frozen plasma; ICU: Intensive care unit; 
MA: Maximal amplitude; MAaa: platelet-fibrin clot tensile strength induced by archidonic acid; MAadp: platelet-fibrin clot tensile strength induced by ADP; 
OR: Odds ratio; PACT: Platelet-activated clotting test; PC: Platelet concentration; PFA: Platelet function analysis; POC: Point of care; PRBC: Packed red 
blood cells; PRU: Platelet reactivity units; rVIIa: Recombinant factor VIIa; ROC: Receiver operating characteristic; TEG: Thromboelastography; TRAP: 
Thrombin receptor activating peptides induced aggregation; U: Units. 
 
